We are live on ! Find out more
Daiwa Securities Group

Daiwa Securities Group Portfolio holdings

AUM $34.8B
1-Year Est. Return 20.7%
This Fund
S&P 500
This Quarter Est. Return
-6.97%
1 Year Est. Return
+20.7%
3 Year Est. Return
+66.64%
5 Year Est. Return
+79.21%
10 Year Est. Return
+192.59%
AUM
$10.4B
AUM Growth
-$1.52B
Cap. Flow
-$723M
Cap. Flow %
-6.93%
Top 10 Hldgs %
32.83%
Holding
1,239
New
73
Increased
466
Reduced
278
Closed
97

Sector Composition

Rank Sector Weight
1 Real Estate 74.77%
2 Technology 3.37%
3 Industrials 3.06%
4 Financials 2.76%
5 Healthcare 2.49%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
RETA
1026
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$6K ﹤0.01%
110
APTX
1027
DELISTED
Aptinyx Inc. Common Stock
APTX
$6K ﹤0.01%
+350
New +$8.28K
DRNA
1028
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$6K ﹤0.01%
+600
New +$7.89K
LMNX
1029
DELISTED
Luminex Corp
LMNX
$6K ﹤0.01%
243
AMPH icon
1030
Amphastar Pharmaceuticals
AMPH
$845M
$5K ﹤0.01%
254
EDIT icon
1031
Editas Medicine
EDIT
$413M
$5K ﹤0.01%
233
EOLS icon
1032
Evolus
EOLS
$412M
$5K ﹤0.01%
+400
New +$5.7K
MNOV icon
1033
MediciNova
MNOV
$63.5M
$5K ﹤0.01%
+600
New +$5.99K
PACB icon
1034
Pacific Biosciences
PACB
$429M
$5K ﹤0.01%
642
QTRX icon
1035
Quanterix
QTRX
$179M
$5K ﹤0.01%
+250
New +$4.49K
SGMO
1036
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$5K ﹤0.01%
467
STIM icon
1037
Neuronetics
STIM
$123M
$5K ﹤0.01%
+250
New +$5.49K
TVTX icon
1038
Travere Therapeutics
TVTX
$5.45B
$5K ﹤0.01%
217
TXMD icon
1039
TherapeuticsMD
TXMD
$24.2M
$5K ﹤0.01%
24
XERS icon
1040
Xeris Biopharma Holdings
XERS
$1.45B
$5K ﹤0.01%
+300
New +$6.02K
SPPI
1041
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
$5K ﹤0.01%
556
CLVS
1042
DELISTED
Clovis Oncology, Inc.
CLVS
$5K ﹤0.01%
271
ELOX
1043
DELISTED
Eloxx Pharmaceuticals, Inc. Common Stock
ELOX
$5K ﹤0.01%
+10
New +$5.52K
TBIO
1044
DELISTED
Translate Bio, Inc. Common Stock
TBIO
$5K ﹤0.01%
+650
New +$4.76K
EIDX
1045
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
$5K ﹤0.01%
+350
New +$4.42K
MNTA
1046
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$5K ﹤0.01%
422
FTSV
1047
DELISTED
Forty Seven, Inc. Common Stock
FTSV
$5K ﹤0.01%
+300
New +$4.58K
BCRX icon
1048
BioCryst Pharmaceuticals
BCRX
$2.5B
$4K ﹤0.01%
544
CNP icon
1049
PUT
CenterPoint Energy
CNP
$29B
$4K ﹤0.01%
995
+495
+99% +$13.8K
IOVA icon
1050
Iovance Biotherapeutics
IOVA
$2.28B
$4K ﹤0.01%
401

Similar funds

Daiwa Securities Group's Q4 2018 Portfolio in Review

As of Q4 2018, Daiwa Securities Group held 1,239 positions worth $10.4B, down 13% from $11.9B the previous quarter. Its ten largest holdings account for 33% of the portfolio.

Daiwa Securities Group withdrew a net $723M in Q4 2018, closing 97 positions and reducing 278 holdings. Its most notable exit was Steris, an estimated $11.9M position sold in full.

By sector, the portfolio is most concentrated in Real Estate at 75% of assets, up from 72% a quarter earlier, followed by Technology and Industrials.

Against the trend, Daiwa Securities Group opened a new position in SITE Centers worth $138M.

  • Daiwa Securities Group's largest Q4 2018 buy was SITE Centers: 16,021,815 shares worth $138M.
  • Daiwa Securities Group added most to American Tower in Q4 2018, an estimated $128M increase.
  • Daiwa Securities Group's biggest Q4 2018 reduction was Crown Castle, cutting an estimated $211M.
  • Daiwa Securities Group fully exited Steris in Q4 2018, selling an estimated $11.9M.
  • Daiwa Securities Group's ten largest holdings make up 33% of its $10.4B portfolio in Q4 2018.
  • Daiwa Securities Group opened 73 new positions and closed 97 in Q4 2018.
  • Daiwa Securities Group's portfolio value fell 13% quarter-over-quarter to $10.4B.

Based on Daiwa Securities Group's 13F filing for Q4 2018, filed 5 Feb 2019.